Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 963-969

  Janckila, Anthony J ^a,b   Lin, Hseun Fu ^c   Wu, Yi Ying ^c   Ku, Chih Hung ^c   Yang, Shih Ping ^c   Lin, Wei Shiang ^c   Lee, Su Huei ^c   Yam, Lung T ^a,b   Chao, Tsu Yi ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atherosclerosis; Cardiovascular risk; Inflammation; Macrophage; Myocardial infarction; Tartrate resistant acid phosphatase

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 6; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM 5A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; YOUNG ADULT;

EID: 79954987830     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.035     Document Type: Article

References (36)

1. Ross R.R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
3. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
4. Packard R.R.S., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
5. Musunuru K., Kral B.G., Blumenthal R.S., et al. The use of high sensitivity C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med 2008, 5:621-635.
6. Sukhija R., Fahdi I., Garza L., et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol 2007, 99:879-884.
7. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R. Danesh. J (Writing committee). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
8. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
9. Antoniades C., Antonopoulos A.S., Tousoulis D., Marinou K., Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009, 30:6-15.
10. Kaptoge S., White I.R., Thompson S.G., et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154, 211 adults in 31 prospective studies. Am J Epidemiol 2007, 166:867-879.
11. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009, 302:49-57.
12. Lerman A., McConnell J.P. Lipoprotein-A associated phospholipase A2: a risk marker or a risk factor?. Am J Cardiol 2008, 101(suppl):11F-22F.
13. Moss D.W. Changes in enzyme expression related to differentiation and regulatory factors: the acid phosphatase of osteoclasts and other macrophages. Clin Chim Acta 1992, 209:131-138.
14. Janckila A.J., Yam L.T. Biology and clinical significance of tartrate-resistant acid phosphatases. New perspectives on an old enzyme. Calcif Tiss Int 2010, 85:465-483.
15. Hayman A.R., Warburton M.J., Pringle J.A.S., Coles B., Chambers T.J. Purification and characterization of a tartrate-resistant acid phosphatase from human osteoclastomas. Biochem J 1989, 261:601-609.
16. Rissanen J.P., Suominen M.I., Peng Z., Halleen J.M. Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tiss Int 2008, 82:108-115.
17. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel marker of bone resorption. J Bone Miner Res 2000, 15:1337-1345.
18. Janckila A.J., Neustadt D.H., Nakasato Y.R., Halleen J.M., Hentunen T., Yam L.T. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002, 320:49-58.
19. Janckila A.J., Parthasarathy R.N., Parthasarathy L.K., et al. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol 2005, 77:209-218.
20. Hayman A.R., Macary P., Lehner P.J., Cox T.M. Tartrate-resistant acid phosphatase (Acp5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001, 49:675-683.
21. Janckila A.J., Slone S.P., Lear S.C., Martin A., Yam L.T. Tartrate-resistant acid phosphatase as an immunohistochemical marker for inflammatory macrophages. Am J Clin Pathol 2007, 127:556-566.
22. Janckila A.J., Neustadt D.H., Yam L.T. Significance of serum TRACP in rheumatoid arthritis. J Bone Miner Res 2008, 23:1287-1295.
23. Janckila A.J., Lederer E.D., Price B.A., Yam L.T. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease. Clin Nephrol 2009, 71:387-396.
24. Shih K.C., Janckila A.J., Kwok C.F., Ho L.T., Chou Y.C., Chao T.Y. Effects of exercise on insulin sensitivity, inflammatory cytokines and serum tartrate-resistant acid phosphatase 5a in obese Chinese male adolescents. Metabolism 2010, 59:144-151.
25. Full L.E., Ruisanchez C., Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009, 11:217-226.
26. Libby P. Atherosclerosis. Vascular Medicine 2006, 101-118. Saunders Elsever, Philadelphia. M.A. Creager, V.J. Dzau, J. Loscalzo (Eds.).
27. Chao T.Y., Lee S.H., Chen M.M., et al. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clin Chim Acta 2005, 359:132-140.
28. Halleen J.M., Ylipahkala H., Alatalo S.L., et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tiss Int 2002, 71:20-25.
29. Weintraub H.S. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol 2008, 101(suppl):3F-10F.
30. Albert C.M., Ma J., Rifai N., Stampfer M.J., Ridker P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002, 105:2595-2599.
31. Sattar N., Murray H.M., Welsh P., et al. Are markers of inflammation more strongly associated with risk for fatal than nonfatal vascular events?. PLoS Med 2009, 6:e1000099. 10.1371/journal.pmed.1000099.
32. Sun H., Koike T., Ichikawa T., et al. C-reactive protein in atherosclerotic lesions. Its origin and pathophysiological significance. Am J Pathol 2005, 167:1139-1148.
33. Devaraj S., Du Clos T.W., Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arteroscler Thromb Vasc Biol 2005, 25:1359-1363.
34. Hayman A.R., Cox T.M. Purple acid phosphatase of the human macrophage and osteoclast. Characterization, molecular properties, and crystallization of teh recombinant di-iron-oxo protein secreted by baculovirus-infected insect cells. J Biol Chem 1994, 269:1294-1300.
35. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
36. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., Matteson E.L. Extra-articular manifestations in rheumatoid arthritis: incidence trends and risk factors over 46years. Ann Rheum Dis 2003, 62:722-727.